J Korean Med Sci.  2008 Aug;23(4):635-643. 10.3346/jkms.2008.23.4.635.

Clinical Features and Treatment Outcomes of Upper Gastrointestinal Bleeding in Patients with Cirrhosis

• Seo YS
• Kim YH
• Ahn SH
• Yu SK
• Baik SK
• Choi SK
• Heo J
• Hahn T
• Yoo TW
• Cho SH
• Lee HW
• Kim JH
• Cho M
• Park SH
• Kim BI
• Han KH
• Um SH

• KMID: 1785822
• DOI: http://doi.org/10.3346/jkms.2008.23.4.635

Abstract

With recent progress in treatment modalities, mortality from upper gastrointestinal (UGI) bleeding has decreased appreciably. The aim of this study was to establish how UGI bleeds are managed in Korean patients with cirrhosis and to evaluate treatment outcomes. A total of 479 episodes of acute UGI bleeding in 464 patients with cirrhosis were included during a six-month period at nine tertiary medical centers. Treatment outcomes were assessed by failure to control bleeding, rebleeding and mortality. The source of bleeding was esophagogastric varices in 77.7% of patients, nonvariceal lesions in 15.9%, and undefined in 6.5%. For control of bleeding, endoscopic and pharmacologic treatments were used in 74.7% and 81.9% of patients, respectively. Variceal ligation was a major technique for endoscopic treatment (90%), and terlipressin and somatostatin were the main pharmacologic agents used (96.4%). Initial hemostasis was achieved in 86.8% of cases, but rebleeding occurred in 3.8% and 16.8% of cases within five days and six weeks of hemorrhage, respectively. Five-day and six-week mortality were 11.3% and 25.9%, respectively. Survival of patients with variceal bleeding seems to be remarkably improved than previous reports, which may suggest the advances in hemostatic methods for control of variceal hemorrhage..

Keyword

Liver Cirrhosis; Varicose Veins; Hemorrhage; Hemostasis; Prevention and Control; Prognosis

MeSH Terms

Adult
Aged
Cohort Studies
Female
Gastrointestinal Hemorrhage/mortality/*therapy
Hemostatic Techniques
Humans
Infection/epidemiology
Liver Cirrhosis/*complications
Lysine Vasopressin/analogs & derivatives/therapeutic use
Male
Middle Aged
Treatment Outcome

Figure

• 

  Fig. 1 Cumulative incidence of rebleeding after hemostasis according to the source of initial bleeding in 448 patients with known source of bleeding. Thirty-one patients with bleeding from undefined sources were excluded in this analysis. The p value was obtained from the log-rank test.

• 

  Fig. 2 (A) Cumulative mortality according to the source of initial bleeding in 448 patients with known source of bleeding. Thirty-one patients with bleeding from undefined sources were excluded in this analysis. (B) In this figure, patients with bleeding from undefined sources were included in patients with variceal bleeding. The p value was obtained from the log-rank test.

• 

  Fig. 3 Cumulative mortalities according to the Child-Pugh class of (A) 448 patients with known sources of bleeding and (B) 372 patients with variceal bleeding. Thirty-one patients with bleeding from undefined sources were excluded in this analysis. The p values were obtained from the log-rank test. Child A, patients with Child-Pugh class A; Child B, patients with Child-Pugh class B; Child C, patients with Child-Pugh class C.

Reference

1. Nachlas MM, O'Neil JE, Campbell AJ. The life history of patients with cirrhosis of the liver and bleeding esophageal varices. Ann Surg. 1955. 141:10–23.

2. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology. 1981. 80:800–809.

3. Pinto HC, Abrantes A, Esteves AV, Almeida H, Correia JP. Long-term prognosis of patients with cirrhosis of the liver and upper gastrointestinal bleeding. Am J Gastroenterol. 1989. 84:1239–1243.

4. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973. 60:646–649.

5. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004. 40:652–659.

6. El-Serag HB, Everhart JE. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol. 2000. 95:3566–3573.

7. McCormick PA, O'Keefe C. Improving prognosis following a first variceal haemorrhage over four decades. Gut. 2001. 49:682–685.

8. Chalasani N, Kahi C, Francois F, Pinto A, Marathe A, Bini EJ, Pandya P, Sitaraman S, Shen J. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol. 2003. 98:653–659.

9. D'Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003. 38:599–612.

10. Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med. 1981. 305:1371–1374.

11. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology. 1995. 22:332–354.

12. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med. 1995. 123:280–287.

13. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998. 27:1207–1212.

14. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005. 43:167–176.

15. Park DK, Um SH, Lee JW, Lee JB, Kim YS, Park CH, Jin YT, Chun HJ, Lee HS, Lee SW, Choi JH, Kim CD, Ryu HS, Hyun JH. Clinical significance of variceal hemorrhage in recent years in patients with liver cirrhosis and esophageal varices. J Gastroenterol Hepatol. 2004. 19:1042–1051.

16. Beppu K, Inokuchi K, Koyanagi N, Nakayama S, Sakata H, Kitano S, Kobayashi M. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc. 1981. 27:213–218.

17. Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology. 1992. 16:1343–1349.

18. de Franchis R. Developing consensus in portal hypertension. J Hepatol. 1996. 25:390–394.

19. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000. 33:846–852.

20. Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Levy VG. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology. 1996. 24:802–806.

21. Kim YS, Um SH, Ryu HS, Lee JB, Lee JW, Park DK, Kim YS, Jin YT, Chun HJ, Lee HS, Lee SW, Choi JH, Kim CD, Hyun JH. The prognosis of liver cirrhosis in recent years in Korea. J Korean Med Sci. 2003. 18:833–841.

22. Luca A, Garcia-Pagan JC, Bosch J, Feu F, Caballeria J, Groszmann RJ, Rodes J. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology. 1997. 112:1284–1289.

23. Oshita M, Takei Y, Kawano S, Yoshihara H, Hijioka T, Fukui H, Goto M, Masuda E, Nishimura Y, Fusamoto H, Kamada T. Roles of endothelin-1 and nitric oxide in the mechanism for ethanol-induced vasoconstriction in rat liver. J Clin Invest. 1993. 91:1337–1342.

24. Heresbach D, Jacquelinet C, Nouel O, Chaperon J, Bretagne JF, Gosselin M. Sclerotherapy versus ligation in hemorrhage caused by rupture of esophageal varices. Direct meta-analysis of randomized trials. Gastroenterol Clin Biol. 1995. 19:914–920.

25. Burroughs AK, Jenkins WJ, Sherlock S, Dunk A, Walt RP, Osuafor TO, Mackie S, Dick R. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med. 1983. 309:1539–1542.

26. Garden OJ, Mills PR, Birnie GG, Murray GD, Carter DC. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial. Gastroenterology. 1990. 98:185–190.

27. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology. 1997. 25:63–70.

28. Sarin SK, Wadhawan M, Gupta R, Shahi H. Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients. Dig Dis Sci. 2005. 50:1538–1547.

29. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med. 1991. 324:1532–1538.